⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Karyopharm Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Karyopharm Therapeutics
↗Newton, Massachusetts, USA
Karyopharm Therapeutics is a commercial-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel cancer therapies. The company is a leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis, primarily through its proprietary SINE (Selective Inhibition of Nuclear Export) technology.
Headquartered in Newton, Massachusetts, Karyopharm focuses on high unmet need cancers, including multiple myeloma, endometrial cancer, and myelofibrosis. Its lead product, XPOVIO (selinexor), is a first-in-class, oral XPO1 inhibitor approved in the U.S. and various international territories.
CLASSIFICATION
SIZE & FINANCIALS
Employees:251-500
Founded:2008
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:KPTI
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Trial Phases:-
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Key Partnerships:Antengene (rights in China/Macau/other Asian territories), Anivive Lifesciences (veterinary oncology)
COMPETITION
Position:Challenger
LEADERSHIP
Key Executives:
Not specified - Management Team
LINKS
Website:karyopharm.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Karyopharm Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.